XellSmart's off-the-shelf cell therapy XS411 met primary safety and tolerability endpoints in a nine-participant Phase I dose-escalation study in moderate-to-advanced Parkinson's disease, with no dose-limiting toxicities, no graft-induced dyskinesia and no aberrant cellular overgrowth on MRI. The company reports OFF-state MDS-UPDRS Part III improvements exceeding 30 points at six months and more than five additional hours of good ON time per day, with 18F-DOPA PET uptake at transplant sites consistent with graft survival and restored dopamine synthesis. A randomized multicenter Phase II trial in China has enrolled 30 participants.
Key Points
- Phase I met safety endpoints with no graft-induced dyskinesia reported
- OFF-state motor scores improved over 30 points at six months
- PET imaging indicated graft survival and restored dopamine synthesis
Longevity Analysis
Replacing lost dopaminergic neurons rather than compensating pharmacologically addresses the structural deficit itself, a shift from symptom management toward tissue restoration in an age-related neurodegenerative disease. The imaging evidence matters as much as the symptom scores: tracer uptake at transplant sites provides an objective readout of engraftment, separating genuine biological repair from the placebo response that open-label neurological trials reliably produce. With nine participants, no control arm and company-reported outcomes, the randomized Phase II data will determine whether the motor and quality-of-life gains hold.
Original published by LT Wire.